EuRBPDB

  • Home
  • Cancer
  • Family
  • Species
  • RBPredictor
  • Search
  • Download
  • Submit
  • Help
  • Contact
TCGA tumor abbreviations
  • ACCAdrenocortical carcinoma
  • BLCABladder Urothelial Carcinoma
  • BRCABreast invasive carcinoma
  • CESCCervical squamous cell carcinoma and endocervical adenocarcinoma
  • CHOLCholangio carcinoma
  • COADColon adenocarcinoma
  • DLBCLymphoid Neoplasm Diffuse Large B-cell Lymphoma
  • ESCAEsophageal carcinoma
  • GBMGlioblastoma multiforme
  • HNSCHead and Neck squamous cell carcinoma
  • KICHKidney Chromophobe
  • KIRCKidney renal clear cell carcinoma
  • KIRPKidney renal papillary cell carcinoma
  • LAMLAcute Myeloid Leukemia
  • LGGBrain Lower Grade Glioma
  • LIHCLiver hepatocellular carcinoma
  • LUADLung adenocarcinoma
  • LUSCLung squamous cell carcinoma
  • MESOMesothelioma
  • OVOvarian serous cystadenocarcinoma
  • PAADPancreatic adenocarcinoma
  • PCPGPheochromocytoma and Paraganglioma
  • PRADProstate adenocarcinoma
  • READRectum adenocarcinoma
  • SARCSarcoma
  • SKCMSkin Cutaneous Melanoma
  • STADStomach adenocarcinoma
  • TGCTThyroid carcinoma
  • THCAThyroid carcinoma
  • THYMThymoma
  • UCECUterine Corpus Endometrial Carcinoma
  • UCSUterine Carcinosarcoma
  • UVMUveal Melanoma

Note: Click here to get the extension of tumor abbreviations.


  • Cancer Related Information
  • Basic Information

Cancer associated literatures
PIDTitleArticle TimeAuthorDoi
24323026Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.J Clin Oncol2014 Jan 10Gandhi Ldoi: 10.1200/JCO.2012.47.2787
26506516Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.Oncotarget2015 Dec 8Qi Wdoi: 10.18632/oncotarget.5659.
25491778The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.Breast Cancer Res Treat2015 JanBean JRdoi: 10.1007/s10549-014-3201-6
20009539Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models.Cancer Biol Ther2009 OctChang Q-
21744334Selective gene expression profiling of mTOR-associated tumor suppressor and oncogenes in ovarian cancer.Folia Histochem Cytobiol2011Lauda??ski P-
25962638Butein suppresses cervical cancer growth through the PI3K/AKT/mTOR pathway.Oncol Rep2015 JunBai Xdoi: 10.3892/or.2015.3922
25478811mTOR and PDGF pathway blockade inhibits liver metastasis of colorectal cancer by modulating the tumor microenvironment.Am J Pathol2015 FebYuge Rdoi: 10.1016/j.ajpath.2014.10.014
20030877Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy.Breast Cancer Res2009Di Cosimo Sdoi: 10.1186/bcr2444
25046358A novel small-molecule compound diaporine A inhibits non-small cell lung cancer growth by regulating miR-99a/mTOR signaling.Cancer Biol Ther2014 OctSong Ydoi: 10.4161/cbt.29925
22907434ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer.Oncogene2013 Jul 11Du Wdoi: 10.1038/onc.2012.359
20226010Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo.Mol Cancer2010 Mar 12Roulin Ddoi: 10.1186/1476-4598-9-57.
26523512Propofol promotes cell apoptosis via inhibiting HOTAIR mediated mTOR pathway in cervical cancer.Biochem Biophys Res Commun2015 Dec 25Zhang Ddoi: 10.1016/j.bbrc.2015.10.129
28377226Aquaporin 3 facilitates tumor growth in pancreatic cancer by modulating mTOR signaling.Biochem Biophys Res Commun2017 May 13Huang Xdoi: 10.1016/j.bbrc.2017.03.168
27153561Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors.Oncotarget2016 Jun 14Faes Sdoi: 10.18632/oncotarget.9134.
29233126Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients.BMC Cancer2017 Dec 12Cao GDdoi: 10.1186/s12885-017-3851-y.
27507059Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC.Oncotarget2016 Sep 13Piao Jdoi: 10.18632/oncotarget.11109.
21266827Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1α regulation in human breast cancer.Pathobiology2010Koo JSdoi: 10.1159/000320936
24469052p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.Oncogene2015 Jan 29Akeno Ndoi: 10.1038/onc.2013.589
27034171Rheb may complex with RASSF1A to coordinate Hippo and TOR signaling.Oncotarget2016 Jun 7Nelson Ndoi: 10.18632/oncotarget.8447.
25110431Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells.World J Gastroenterol2014 Aug 7Spampatti Mdoi: 10.3748/wjg.v20.i29.10038.
26418749Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.Oncotarget2015 Oct 20Wu Mdoi: 10.18632/oncotarget.5018.
25341684SKLB-M8 induces apoptosis through the AKT/mTOR signaling pathway in melanoma models and inhibits angiogenesis with decrease of ERK1/2 phosphorylation.J Pharmacol Sci2014Wang J-
21383697MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.Oncogene2011 Aug 11Oneyama Cdoi: 10.1038/onc.2011.63
16929481Carcinoma-associated eIF3i overexpression facilitates mTOR-dependent growth transformation.Mol Carcinog2006 DecAhlemann M-
26261591Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localization.Int J Clin Exp Pathol2015 Jun 1Melling N-
19090006Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas.Cancer2009 Jan 1Dobashi Ydoi: 10.1002/cncr.23996.
21859551[Advances of LKB1-AMPK-mTOR Signaling Pathway in Tumor].Zhongguo Fei Ai Za Zhi2011 AugZhang Xdoi: 10.3779/j.issn.1009-3419.2011.08.09.
26722465Phosphorylated mTOR expression correlates with podoplanin expression and high tumor grade in esophageal squamous cell carcinoma.Int J Clin Exp Pathol2015 Oct 1Chuang WY-
27226604Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma.J Biol Chem2016 Jul 1Holmes Bdoi: 10.1074/jbc.M116.726927
27012089[REGULATION OF THE mTOR SIGNALING PATHWAY IN MACROPHAGES IN VARIOUS PATHOLOGIES].Tsitologiia2015Zubova SG-
25931349Pro-Apoptotic Activity of Ruxolitinib Alone and in Combination with Hydroxyurea, Busulphan, and PI3K/mTOR Inhibitors in JAK2-Positive Human Cell Lines.Adv Clin Exp Med2015 Mar-AprSzyma??ska Jdoi: 10.17219/acem/32934.
25862847Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.Anticancer Res2015 AprAderhold C-
19098000The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors.J Biol Chem2009 Feb 20Harada Hdoi: 10.1074/jbc.M806653200
18926585Role of TSC-mTOR pathway in diabetic nephropathy.Diabetes Res Clin Pract2008 Nov 13Inoki Kdoi: 10.1016/j.diabres.2008.09.028
25667121The tumor-suppressor gene LZTS1 suppresses colorectal cancer proliferation through inhibition of the AKT-mTOR signaling pathway.Cancer Lett2015 Apr 28Zhou Wdoi: 10.1016/j.canlet.2015.02.004
25778319Sorafenib inhibits liver cancer growth by decreasing mTOR, AKT, and PI3K expression.J BUON2015 Jan-FebZhang CZ-
26255626Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.Oncotarget2015 Jul 20Ghosh AP-
19956179Common corruption of the mTOR signaling network in human tumors.Oncogene2008 DecMenon Sdoi: 10.1038/onc.2009.352.
22871496Pharmacological targeting of mammalian target of rapamycin inhibits ovarian granulosa cell tumor growth.Carcinogenesis2012 NovRico Cdoi: 10.1093/carcin/bgs263
16912159Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.Cancer Res2006 Aug 15Wang MY-
28064317[B7-H4-mediated immunoresistance is supressed by PI3K/Akt/mTOR pathway inhibitors].Mol Biol (Mosk)2016 Nov-DecZeng Sdoi: 10.7868/S0026898416060240.
19147764Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature.Clin Cancer Res2009 Jan 15Murphy JDdoi: 10.1158/1078-0432.CCR-08-1019.
23103253HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.Mol Cell2012 Dec 14Elorza Adoi: 10.1016/j.molcel.2012.09.017
26170313Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.Proc Natl Acad Sci U S A2015 Jul 28Masui Kdoi: 10.1073/pnas.1511759112
25807077Tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mTOR-mediated hexokinase II inhibition--a Warburg-reversing effect.PLoS One2015 Mar 25Lu CLdoi: 10.1371/journal.pone.0121046
22944293Clinicopathologic significance and function of mammalian target of rapamycin activation in esophageal squamous cell carcinoma.Hum Pathol2013 FebKim SHdoi: 10.1016/j.humpath.2012.05.011
17148679Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.Am J Pathol2006 DecPeponi E-
22287548Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway.Cancer Res2012 Mar 15Chen Wdoi: 10.1158/0008-5472.CAN-11-2684
21837670The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas.Cancer2012 Mar 15Setsu Ndoi: 10.1002/cncr.26448
23963361Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-??B and mTOR dual-targeting approach.Mol Cancer Ther2013 OctChaturvedi NKdoi: 10.1158/1535-7163.MCT-13-0239
26208432mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells.Cancer Lett2015 Oct 10Karthik GMdoi: 10.1016/j.canlet.2015.07.017
20668229The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.Blood2010 Nov 18Green ASdoi: 10.1182/blood-2010-02-269837
23878245Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated suppression of mTORC1.Proc Natl Acad Sci U S A2013 Aug 6Tripathi DNdoi: 10.1073/pnas.1307736110
18650380ATF6alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo.Proc Natl Acad Sci U S A2008 Jul 29Schewe DMdoi: 10.1073/pnas.0800939105
20048174Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.J Clin Oncol2010 Feb 10Wagner AJdoi: 10.1200/JCO.2009.25.2981
25854175MicroRNA-199a-3p suppresses glioma cell proliferation by regulating the AKT/mTOR signaling pathway.Tumour Biol2015 SepShen Ldoi: 10.1007/s13277-015-3409-z
26993162FGFR antagonist induces protective autophagy in FGFR1-amplified breast cancer cell.Biochem Biophys Res Commun2016 May 20Chen Ydoi: 10.1016/j.bbrc.2016.03.017
28159681The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).Cancer Lett2017 Apr 28Gazi Mdoi: 10.1016/j.canlet.2017.01.035
27693556Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.Cancer Lett2016 Dec 28Muqbil Idoi: 10.1016/j.canlet.2016.09.016
28419191PPAR?? promotes tumor progression via activation of Glut1 and SLC1-A5 transcription.Carcinogenesis2017 Jul 1Zhang Wdoi: 10.1093/carcin/bgx035.
27835987Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis.BMC Cancer2016 Nov 11Li S-
28582508Association of breast cancer risk and the mTOR pathway in women of African ancestry in 'The Root' Consortium.Carcinogenesis2017 Aug 1Wang Sdoi: 10.1093/carcin/bgx055.
28745319The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.Oncogene2017 Nov 16D'Abronzo LSdoi: 10.1038/onc.2017.233
27147575Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.Oncotarget2016 May 31Dong Ldoi: 10.18632/oncotarget.9061.
27283897Infiltrating macrophages increase RCC epithelial mesenchymal transition (EMT) and stem cell-like populations via AKT and mTOR signaling.Oncotarget2016 Jul 12Yang Zdoi: 10.18632/oncotarget.9873.
27174915IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma.Oncotarget2016 Aug 16Folgiero Vdoi: 10.18632/oncotarget.9284.
27285754PI3K-PTEN dysregulation leads to mTOR-driven upregulation of the core clock gene BMAL1 in normal and malignant epithelial cells.Oncotarget2016 Jul 5Matsumoto CSdoi: 10.18632/oncotarget.9877.
28002802Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.Oncotarget2017 Jan 31Fourneaux Bdoi: 10.18632/oncotarget.13987.
28498460MCM7 amplification and overexpression promote cell proliferation, colony formation and migration in esophageal squamous cell carcinoma by activating the AKT1/mTOR signaling pathway.Oncol Rep2017 JunQiu YTdoi: 10.3892/or.2017.5614
28440461The role of miR-451 in the switching between proliferation and migration in malignant glioma cells: AMPK signaling, mTOR modulation and Rac1 activation required.Int J Oncol2017 JunZhao Kdoi: 10.3892/ijo.2017.3973
28052030The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo.Oncotarget2017 Jan 31Fujihara Sdoi: 10.18632/oncotarget.14345.
29491094mTORC1 and mTORC2 Expression Levels in Oral Squamous Cell Carcinoma: An Immunohistochemical and Clinicopathological Study.Anticancer Res2018 MarKawasaki G-
28468774Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.Mol Cancer Ther2017 JulGordon MAdoi: 10.1158/1535-7163.MCT-17-0111
28007777Noninvasive Measurement of mTORC1 Signaling with 89Zr-Transferrin.Clin Cancer Res2017 Jun 15Truillet Cdoi: 10.1158/1078-0432.CCR-16-2448
28624790Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development.Oncotarget2017 Jul 18Cheng Hdoi: 10.18632/oncotarget.18207.
28791373Downregulation of BZW2 inhibits osteosarcoma cell growth by inactivating the Akt/mTOR signaling pathway.Oncol Rep2017 OctCheng DDdoi: 10.3892/or.2017.5890
29048631Autophagy induction enhances tetrandrine-induced apoptosis via the AMPK/mTOR pathway in human bladder cancer cells.Oncol Rep2017 NovKou Bdoi: 10.3892/or.2017.5988
29448085Plk2 Loss Commonly Occurs in Colorectal Carcinomas but not Adenomas: Relationship to mTOR Signaling.Neoplasia2018 MarMatthew EMdoi: 10.1016/j.neo.2018.01.004
30488209Association of Target Therapy Gene Expression with Metastasizing of Clear-Cell Renal Cell Carcinoma.Bull Exp Biol Med2018 DecApanovich NVdoi: 10.1007/s10517-018-4327-z
29403037The mTOR-S6K pathway links growth signalling to DNA damage response by targeting RNF168.Nat Cell Biol2018 MarXie Xdoi: 10.1038/s41556-017-0033-8
18831768TOR complex 2 is needed for cell cycle progression and anchorage-independent growth of MCF7 and PC3 tumor cells.BMC Cancer2008 Oct 3Hietakangas Vdoi: 10.1186/1471-2407-8-282.
20081105A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.Mol Endocrinol2010 FebNagaraja AKdoi: 10.1210/me.2009-0295
23773481Clinical impacts of mammalian target of rapamycin expression in human colorectal cancers.Hum Pathol2013 OctAlqurashi Ndoi: 10.1016/j.humpath.2013.03.014
26097572Expression and clinical significances of Beclin1, LC3 and mTOR in colorectal cancer.Int J Clin Exp Pathol2015 Apr 1Wu S-
24853425SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway.Cell Death Dis2014 May 22Yuan LJdoi: 10.1038/cddis.2014.222.
25843797DEPTOR-related mTOR suppression is involved in metformin's anti-cancer action in human liver cancer cells.Biochem Biophys Res Commun2015 May 15Obara Adoi: 10.1016/j.bbrc.2015.03.148
25531318LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression.Oncogene2015 Sep 24Mura Mdoi: 10.1038/onc.2014.428
23246968The evolution of the TOR pathway and its role in cancer.Oncogene2013 Aug 22Beauchamp EMdoi: 10.1038/onc.2012.567
27315344MicroRNA-224 aggrevates tumor growth and progression by targeting mTOR in gastric cancer.Int J Oncol2016 SepZhang Ydoi: 10.3892/ijo.2016.3581
27109477FXR blocks the growth of liver cancer cells through inhibiting mTOR-s6K pathway.Biochem Biophys Res Commun2016 May 27Huang Xdoi: 10.1016/j.bbrc.2016.04.106
28235484Branched-chain amino acid transaminase 1 (BCAT1) promotes the growth of breast cancer cells through improving mTOR-mediated mitochondrial biogenesis and function.Biochem Biophys Res Commun2017 Apr 29Zhang Ldoi: 10.1016/j.bbrc.2017.02.101
28698135MREG suppresses thyroid cancer cell invasion and proliferation by inhibiting Akt-mTOR signaling.Biochem Biophys Res Commun2017 Sep 9Meng Xdoi: 10.1016/j.bbrc.2017.07.044
27991928Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.Oncogene2017 May 11Mateo Fdoi: 10.1038/onc.2016.427
29307829Blockage of cytosolic phospholipase A2 alpha sensitizes aggressive breast cancer to doxorubicin through suppressing ERK and mTOR kinases.Biochem Biophys Res Commun2018 Jan 29Li Zdoi: 10.1016/j.bbrc.2018.01.016
27533457Impacts of the mTOR gene polymorphisms rs2536 and rs2295080 on breast cancer risk in the Chinese population.Oncotarget2016 Sep 6Zhao Ydoi: 10.18632/oncotarget.11272.
29978609Synergistic Anti-Cancer Effects of AKT and SRC Inhibition in Human Pancreatic Cancer Cells.Yonsei Med J2018 AugAhn Kdoi: 10.3349/ymj.2018.59.6.727.
29749504LSD1 negatively regulates autophagy through the mTOR signaling pathway in ovarian cancer cells.Oncol Rep2018 JulWei Ydoi: 10.3892/or.2018.6432
30061533mTOR and Tumor Cachexia.Int J Mol Sci2018 Jul 30Duval APdoi: 10.3390/ijms19082225.
30171261mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer.Oncogene2019 JanLiang SQdoi: 10.1038/s41388-018-0479-6
26287940Genetic variations in the mTOR gene contribute toward gastric adenocarcinoma susceptibility in an Eastern Chinese population.Pharmacogenet Genomics2015 NovWang MYdoi: 10.1097/FPC.0000000000000163.
26201060The role of mTOR during cisplatin treatment in an in vitro and ex vivo model of cervical cancer.Toxicology2015 Sep 1Leisching GRdoi: 10.1016/j.tox.2015.07.010
26311737Licochalcone A induces autophagy through PI3K/Akt/mTOR inactivation and autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells.Oncotarget2015 Oct 6Tsai JPdoi: 10.18632/oncotarget.4767.
23530221Hypoxia induces a phase transition within a kinase signaling network in cancer cells.Proc Natl Acad Sci U S A2013 Apr 9Wei Wdoi: 10.1073/pnas.1303060110
26319900Suppression of the GTPase-activating protein RGS10 increases Rheb-GTP and mTOR signaling in ovarian cancer cells.Cancer Lett2015 Dec 1Altman MKdoi: 10.1016/j.canlet.2015.08.012
24556942Limited significance of activated Akt-mammalian target of rapamycin signaling pathway in prostate cancer progression.Urol Int2014Ko YHdoi: 10.1159/000356262
26427150Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.Clin Lab2015Ji Y-
25421824Wedelolactone inhibits breast cancer-induced osteoclastogenesis by decreasing Akt/mTOR signaling.Int J Oncol2015 FebHsieh CJdoi: 10.3892/ijo.2014.2769
19739122Prognostic role of p-mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer.Int J Cancer2010 Jun 15An JYdoi: 10.1002/ijc.24872.
20204306RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.Oncol Rep2010 AprWang ZG-
20354165Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancer.Cancer Prev Res (Phila)2010 AprLin Jdoi: 10.1158/1940-6207.CAPR-09-0263
26238185MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.Oncotarget2015 Sep 22Xu Sdoi: 10.18632/oncotarget.4762.
22127531mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry.Surg Today2012 MayWang Ldoi: 10.1007/s00595-011-0028-1
25632222Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancreatic cancer cells.Drug Des Devel Ther2015 Jan 17Wang Fdoi: 10.2147/DDDT.S73689
19553815Promising molecular targets in ovarian cancer.Curr Opin Oncol2009 SepBlagden Sdoi: 10.1097/CCO.0b013e32832eab1f.
25854169Metformin inhibits thyroid cancer cell growth, migration, and EMT through the mTOR pathway.Tumour Biol2015 AugHan Bdoi: 10.1007/s13277-015-3315-4
23832540Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.Tumour Biol2013 DecYothaisong Sdoi: 10.1007/s13277-013-0945-2
27090655Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer.BMC Syst Biol2016 Apr 18Andorfer Pdoi: 10.1186/s12918-016-0278-z.
21276607Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer.Gynecol Oncol2011 AprNo JHdoi: 10.1016/j.ygyno.2010.12.364
19164214Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.J Clin Oncol2009 Feb 20Hildebrandt MAdoi: 10.1200/JCO.2008.17.6297
20019839CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells.Neoplasia2009 DecRoca H-
21177869mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells.J Biol Chem2011 Feb 25Liu Jdoi: 10.1074/jbc.M110.183087
18413763A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.Cancer Res2008 Apr 15Shor Bdoi: 10.1158/0008-5472.CAN-07-6487.
20153512Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma.Hum Pathol2010 JunBunkholt Elstrand Mdoi: 10.1016/j.humpath.2009.09.017
20093977Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer.J Thorac Oncol2010 MarDhillon Tdoi: 10.1097/JTO.0b013e3181ce6604.
23423739Genetic variations of mTORC1 genes and risk of gastric cancer in an Eastern Chinese population.Mol Carcinog2013 NovHe Jdoi: 10.1002/mc.22013
25460505DNA damage-induced S and G2/M cell cycle arrest requires mTORC2-dependent regulation of Chk1.Oncotarget2015 Jan 1Selvarajah J-
25632225Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.Drug Des Devel Ther2015 Jan 17Wang Fdoi: 10.2147/DDDT.S75221
19897009The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.Mol Cell Endocrinol2010 May 28Saji Mdoi: 10.1016/j.mce.2009.10.016
26577839Genetic variants in the mTOR pathway and breast cancer risk in African American women.Carcinogenesis2016 JanCheng TDdoi: 10.1093/carcin/bgv160
15802268Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha.J Biol Chem2005 Jun 10Phillips RJ-
19949304The role of mTOR in bladder cancer.Cancer Biol Ther2009 DecGust KM-
23940798Polymorphisms in the mTOR gene and risk of sporadic prostate cancer in an Eastern Chinese population.PLoS One2013 Aug 5Li Qdoi: 10.1371/journal.pone.0071968
25051360Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.Oncotarget2014 Jul 15Davis NM-
27220494MiR-21 modulates radiosensitivity of cervical cancer through inhibiting autophagy via the PTEN/Akt/HIF-1α feedback loop and the Akt-mTOR signaling pathway.Tumour Biol2016 SepSong L-
25108739Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival.Breast Cancer Res Treat2014 SepPande Mdoi: 10.1007/s10549-014-3081-9
25043667Expression of phosphorylated-mTOR during the development of prostate cancer.Prostate2014 SepSutherland SIdoi: 10.1002/pros.22840
18702307[Role of PTEN protein in multidrug resistance of prostate cancer cells].Mol Biol (Mosk)2008 May-JunSherbakova EA-
23886172Prognostic value of phosphorylated mTOR/RPS6KB1 in non- small cell lung cancer.Asian Pac J Cancer Prev2013Zhang Y-
23623586Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer.Hum Pathol2013 SepFahmy Mdoi: 10.1016/j.humpath.2012.11.026
17409838Targeting mTOR signaling for lung cancer therapy.J Thorac Oncol2006 FebSun SY-
12813467Phospholipase D confers rapamycin resistance in human breast cancer cells.Oncogene2003 Jun 19Chen Y-
18570873mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation.Mol Cell2008 Jun 20Hong Fdoi: 10.1016/j.molcel.2008.04.027.
23322780Mutations in critical domains confer the human mTOR gene strong tumorigenicity.J Biol Chem2013 Mar 1Murugan AKdoi: 10.1074/jbc.M112.399485
27055253Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.PLoS One2016 Apr 7Cardnell RJdoi: 10.1371/journal.pone.0152584
20727662Clinical significance of pmTOR expression in endometrioid endometrial carcinoma.Eur J Obstet Gynecol Reprod Biol2010 DecChoi CHdoi: 10.1016/j.ejogrb.2010.07.038
17616691AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.Cancer Res2007 Jul 1Liu LZ-
18622747Mammalian target of rapamycin pathway inhibition enhances the effects of 5-aza-dC on suppressing cell proliferation in human gastric cancer cell lines.Sci China C Life Sci2008 JulSun Ddoi: 10.1007/s11427-008-0080-2
26158266Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells.PLoS One2015 Jul 9Woo YMdoi: 10.1371/journal.pone.0132285
22367541The translational landscape of mTOR signalling steers cancer initiation and metastasis.Nature2012 Feb 22Hsieh ACdoi: 10.1038/nature10912.
20805015Phospholipase D-mTOR requirement for the Warburg effect in human cancer cells.Cancer Lett2010 Dec 18Toschi Adoi: 10.1016/j.canlet.2010.08.006.
20630061Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.BMC Cancer2010 Jul 14Javle MMdoi: 10.1186/1471-2407-10-368.
25735853A liaison between mTOR signaling, ribosome biogenesis and cancer.Biochim Biophys Acta2015 JulGentilella Adoi: 10.1016/j.bbagrm.2015.02.005
26639561BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.Sci Rep2015 Dec 7Karachaliou Ndoi: 10.1038/srep17499.
19624311GOLPH3 links the Golgi network to mTOR signaling and human cancer.Pigment Cell Melanoma Res2009 AugAbraham RTdoi: 10.1111/j.1755-148X.2009.00596.x.
22684558Suppression of EphB4 improves the inhibitory effect of mTOR shRNA on the biological behaviors of ovarian cancer cells by down-regulating Akt phosphorylation.J Huazhong Univ Sci Technolog Med Sci2012 JunMa Xdoi: 10.1007/s11596-012-0062-2
25659153Tanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway.PLoS One2015 Feb 6Li Gdoi: 10.1371/journal.pone.0117440
19020722Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis.Oncol Rep2008 DecNoske A-
21372221Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.Clin Cancer Res2011 Apr 15Santiskulvong Cdoi: 10.1158/1078-0432.CCR-10-2289
24334141mTOR-dependent transcriptional repression of Pdcd4 tumor suppressor in lung cancer cells.Biochim Biophys Acta2014 JanVikhreva PNdoi: 10.1016/j.bbagrm.2013.12.001
26823699Oleanolic acid suppresses the proliferation of human bladder cancer by Akt/mTOR/S6K and ERK1/2 signaling.Int J Clin Exp Pathol2015 Nov 1Mu DW-
22983984Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway.Carcinogenesis2012 DecIwaya Tdoi: 10.1093/carcin/bgs288
24695460Downregulation of mTOR by lentivirus inhibits prostate cancer cell growth.Int J Clin Exp Pathol2014 Feb 15Du YF-
26160839Halofuginone inhibits colorectal cancer growth through suppression of Akt/mTORC1 signaling and glucose metabolism.Oncotarget2015 Sep 15Chen GQ-
22029423Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways.Radiat Oncol2011 Oct 26Rashid Adoi: 10.1186/1748-717X-6-144.
24571487Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells.Respir Res2014 Feb 26Kim EYdoi: 10.1186/1465-9921-15-26.
24816861Association of mTOR polymorphisms with cancer risk and clinical outcomes: a meta-analysis.PLoS One2014 May 9Shao Jdoi: 10.1371/journal.pone.0097085
23841076The omega-3 polyunsaturated fatty acid DHA induces simultaneous apoptosis and autophagy via mitochondrial ROS-mediated Akt-mTOR signaling in prostate cancer cells expressing mutant p53.Biomed Res Int2013Shin Sdoi: 10.1155/2013/568671
17693255IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway.Cell2007 Aug 10Lee DF-
19223902Relation between outcomes and localisation of p-mTOR expression in gastric cancer.Br J Cancer2009 Mar 10Murayama Tdoi: 10.1038/sj.bjc.6604915
18776922Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.Oncogene2008 Nov 27Wang Ydoi: 10.1038/onc.2008.318
20479250PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.Proc Natl Acad Sci U S A2010 Jun 1Loi Sdoi: 10.1073/pnas.0907011107
25600244Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.Clin Breast Cancer2015 JunYanai Adoi: 10.1016/j.clbc.2014.12.002
21277936Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.Exp Hematol2011 AprBatista Adoi: 10.1016/j.exphem.2011.01.005
24624456PTEN/PI3K/mTOR/B7-H1 signaling pathway regulates cell progression and immuno-resistance in pancreatic cancer.Hepatogastroenterology2013 OctZhang Y-
22471665Targeting PI3 kinase/AKT/mTOR signaling in cancer.Crit Rev Oncog2012Sheppard K-
20061787Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer.Cancer Biol Ther2009 DecMansure JJ-
25029414Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.J Clin Endocrinol Metab2014 OctMalaguarnera Rdoi: 10.1210/jc.2013-3976
26012635HER2-mTOR signaling-driven breast cancer cells require ER-associated degradation to survive.Sci Signal2015 May 26Singh Ndoi: 10.1126/scisignal.aaa6922.
26267321The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.Oncotarget2015 Sep 22Bai Hdoi: 10.18632/oncotarget.4550.
26652716MMP2 and MMP7 at the invasive front of gastric cancer are not associated with mTOR expression.Diagn Pathol2015 Dec 12Bornschein Jdoi: 10.1186/s13000-015-0449-z.
26339598Docosahexaenoic Acid Induces Cell Death in Human Non-Small Cell Lung Cancer Cells by Repressing mTOR via AMPK Activation and PI3K/Akt Inhibition.Biomed Res Int2015Kim Ndoi: 10.1155/2015/239764
23555892A polymorphism (rs2295080) in mTOR promoter region and its association with gastric cancer in a Chinese population.PLoS One2013Xu Mdoi: 10.1371/journal.pone.0060080
26235873Inactivated Sendai virus induces apoptosis and autophagy via the PI3K/Akt/mTOR/p70S6K pathway in human non-small cell lung cancer cells.Biochem Biophys Res Commun2015 Sep 11Zhang Qdoi: 10.1016/j.bbrc.2015.07.130
23933173mTOR activation in immature cells of primary nasopharyngeal carcinoma and anti-tumor effect of rapamycin in vitro and in vivo.Cancer Lett2013 Dec 1Yang Cdoi: 10.1016/j.canlet.2013.08.004
21325052Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth.Proc Natl Acad Sci U S A2011 Mar 8Sun Qdoi: 10.1073/pnas.1014769108
24637915MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression.PLoS One2014 Mar 17Hu Ydoi: 10.1371/journal.pone.0092099
15028555G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.Am J Physiol Cell Physiol2004 AugGao N-
26432419Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer.Cancer Sci2015 DecYamaguchi Hdoi: 10.1111/cas.12828
21412012Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer.Oncology2010Kim JGdoi: 10.1159/000320761
26744318MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR.Oncotarget2016 Feb 2Zhang Bdoi: 10.18632/oncotarget.6790.
24011934Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.Eur J Cancer2013 DecSheppard KEdoi: 10.1016/j.ejca.2013.08.007
25816324Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.PLoS One2015 Mar 27Deng Ldoi: 10.1371/journal.pone.0120511
26585486Activation of mTORC1 under nutrient starvation conditions increases cellular radiosensitivity in human liver cancer cell lines, HepG2 and HuH6.Biochem Biophys Res Commun2015 Dec 25Murata Ydoi: 10.1016/j.bbrc.2015.11.016
24027431TBK1 regulates prostate cancer dormancy through mTOR inhibition.Neoplasia2013 SepKim JK-
18395956Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer.Eur J Obstet Gynecol Reprod Biol2008 AugZhang XYdoi: 10.1016/j.ejogrb.2007.12.021
25918246mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation.Mol Cell Biol2015 JulKoo Jdoi: 10.1128/MCB.01525-14
208117252-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.Int J Oncol2010 OctLi CM-
26935715Anti-proliferative effect of RCE-4 from Reineckia carnea on human cervical cancer HeLa cells by inhibiting the PI3K/Akt/mTOR signaling pathway and NF-??B activation.Naunyn Schmiedebergs Arch Pharmacol2016 JunBai Cdoi: 10.1007/s00210-016-1217-7
23178462Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells.Acta Pharmacol Sin2013 FebDong LXdoi: 10.1038/aps.2012.143
20459645Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-kappaB dependent AP-1-mediated ICAM-1 expression in breast cancer cells.Mol Cancer2010 May 7Ahmed Mdoi: 10.1186/1476-4598-9-101.
19020730TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells.Oncol Rep2008 DecWang ZG-
24630930Catalase expression in MCF-7 breast cancer cells is mainly controlled by PI3K/Akt/mTor signaling pathway.Biochem Pharmacol2014 May 15Glorieux Cdoi: 10.1016/j.bcp.2014.02.025
25749387The miR-491-3p/mTORC2/FOXO1 regulatory loop modulates chemo-sensitivity in human tongue cancer.Oncotarget2015 Mar 30Zheng G-
18612547Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cells.Thromb Haemost2008 JulJiang Xdoi: 10.1160/TH07-12-0722.
21339740Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis.Oncogene2011 Jun 30Kim EKdoi: 10.1038/onc.2011.22
26780727Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K/Akt/mTOR signaling pathway.Biochem Biophys Res Commun2016 Feb 5Liu Ydoi: 10.1016/j.bbrc.2016.01.046
22457328.Sci Signal2012 Mar 27Fingar DCdoi: 10.1126/scisignal.2003026.
22349822Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis.Oncogene2013 Jan 10Wen ZHdoi: 10.1038/onc.2012.47
22452883Inhibition of mTORC1 kinase activates Smads 1 and 5 but not Smad8 in human prostate cancer cells, mediating cytostatic response to rapamycin.Mol Cancer Res2012 JunWahdan-Alaswad RSdoi: 10.1158/1541-7786.MCR-11-0615
21886838Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40.PLoS One2011Basu Adoi: 10.1371/journal.pone.0023919
23991038Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling.PLoS One2013 Aug 26Zhang Xdoi: 10.1371/journal.pone.0072053
17911267Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance.Proc Natl Acad Sci U S A2007 Oct 9Zhou J-
18848473The TSC-mTOR signaling pathway regulates the innate inflammatory response.Immunity2008 Oct 17Weichhart Tdoi: 10.1016/j.immuni.2008.08.012
23297825Targeting the mTOR pathway in tumor malignancy.Curr Cancer Drug Targets2013 MarCheng H-
16341243Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.Nat Med2006 JanThomas GV-
21035497Deciphering the signaling pathways of cancer stem cells of glioblastoma multiforme: role of Akt/mTOR and MAPK pathways.Adv Enzyme Regul2011Jhanwar-Uniyal Mdoi: 10.1016/j.advenzreg.2010.09.017
24631838A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.Cancer Discov2014 MayGrabiner BCdoi: 10.1158/2159-8290.CD-13-0929
25128827PGE2-induced colon cancer growth is mediated by mTORC1.Biochem Biophys Res Commun2014 Sep 5Dufour Mdoi: 10.1016/j.bbrc.2014.08.032
19875696Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk.Carcinogenesis2009 DecChen Mdoi: 10.1093/carcin/bgp258.
26427711Anticancer effect of rapamycin on MCF-7 via downregulation of VEGF expression.In Vitro Cell Dev Biol Anim2016 JanFujii Tdoi: 10.1007/s11626-015-9944-5
20145209ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway.Sci Signal2010 Feb 9Kuo HPdoi: 10.1126/scisignal.2000590.
21046231The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.Breast Cancer Res Treat2011 SepBr??nner-Kubath Cdoi: 10.1007/s10549-010-1232-1
26284586mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.Oncotarget2015 Nov 24Hanly EKdoi: 10.18632/oncotarget.4052.
19223493Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer.Clin Cancer Res2009 Mar 1Yu Gdoi: 10.1158/1078-0432.CCR-08-2138
22815832Genetic variations in a PTEN/AKT/mTOR axis and prostate cancer risk in a Chinese population.PLoS One2012Chen Jdoi: 10.1371/journal.pone.0040817
20929525Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer.BMC Cancer2010 Oct 7Xu DZdoi: 10.1186/1471-2407-10-536.
16786123Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy.Oncol Rep2006 JulFaried LS-
22340595Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.Cancer Cell2012 Feb 14Muranen Tdoi: 10.1016/j.ccr.2011.12.024.
17631500Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells.J Biol Chem2007 Sep 7Yoon S-
26617795TMP21 modulates cell growth in papillary thyroid cancer cells by inducing autophagy through activation of the AMPK/mTOR pathway.Int J Clin Exp Pathol2015 Sep 1Xu X-
27796683Akt/AMPK/mTOR pathway was involved in the autophagy induced by vitamin E succinate in human gastric cancer SGC-7901 cells.Mol Cell Biochem2017 JanYu Ydoi: 10.1007/s11010-016-2853-4
26753650Expression of mTOR and its inhibitory effect on cell proliferation and apoptosis of breast cancer cells.J Biol Regul Homeost Agents2015 Oct-DecCheng XF-
19553991GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer.Nature2009 Jun 25Scott KLdoi: 10.1038/nature08109.
24508774Targeting bone metastatic cancer: Role of the mTOR pathway.Biochim Biophys Acta2014 AprBertoldo Fdoi: 10.1016/j.bbcan.2014.01.009
16652388Expression of mTOR signaling pathway markers in prostate cancer progression.Prostate2006 Aug 1Kremer CL-
22399812TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion.J Cell Sci2012 Mar 1Lamouille Sdoi: 10.1242/jcs.095299
18519641Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK.Genes Dev2008 Jun 1Dan HCdoi: 10.1101/gad.1662308.
17545512The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.Clin Cancer Res2007 Jun 1Abraham RT-
26499488Puquitinib mesylate (XC-302) induces autophagy via inhibiting the PI3K/AKT/mTOR signaling pathway in nasopharyngeal cancer cells.Int J Mol Med2015 DecWang KFdoi: 10.3892/ijmm.2015.2378
15580312Alternative phospholipase D/mTOR survival signal in human breast cancer cells.Oncogene2005 Jan 20Chen Y-
27572296RLIP76 increases apoptosis through Akt/mTOR signaling pathway in gastric cancer.Oncol Rep2016 OctWang Wdoi: 10.3892/or.2016.5043
25729885Small molecule schweinfurthins selectively inhibit cancer cell proliferation and mTOR/AKT signaling by interfering with trans-Golgi-network trafficking.Cancer Biol Ther2015Bao Xdoi: 10.1080/15384047.2015.1019184
20190810Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer.Oncogene2010 May 6Sato Tdoi: 10.1038/onc.2010.28
12242281Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.Mol Cell Biol2002 OctHudson CC-
23828865Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells.Endocr Relat Cancer2013 Aug 21Gild MLdoi: 10.1530/ERC-13-0085
23886294miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer.Mol Cancer2013 Jul 25Wei Fdoi: 10.1186/1476-4598-12-81.
24991762CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells.Cell Death Dis2014 Jul 3Ieran?? Cdoi: 10.1038/cddis.2014.269.
21373201Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC).PLoS One2011 Feb 23Campa Ddoi: 10.1371/journal.pone.0016914.
20811722Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.Int J Oncol2010 OctNagata Y-
18652687Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer.BMC Genomics2008 Jul 24Heinonen Hdoi: 10.1186/1471-2164-9-348.
21170086Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 addiction.Oncogene2011 Mar 31Colombi Mdoi: 10.1038/onc.2010.539
26367112MiR-634 decreases cell proliferation and induces apoptosis by targeting mTOR signaling pathway in cervical cancer cells.Artif Cells Nanomed Biotechnol2016 NovCong Jdoi: 10.3109/21691401.2015.1080171
24668416miR-99a and -99b inhibit cervical cancer cell proliferation and invasion by targeting mTOR signaling pathway.Med Oncol2014 MayWang Ldoi: 10.1007/s12032-014-0934-3
22685542microRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion.PLoS One2012Dey Ndoi: 10.1371/journal.pone.0037366
17616684Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha.Cancer Res2007 Jul 1Dan HC-
18787170FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.Science2008 Sep 12Mao JHdoi: 10.1126/science.1162981.
22952422Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.Neoplasia2012 AugWeekes CD-
27959445Delphinidin inhibits angiogenesis through the suppression of HIF-1α and VEGF expression in A549 lung cancer cells.Oncol Rep2017 FebKim MHdoi: 10.3892/or.2016.5296
284081374-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.Toxicol Appl Pharmacol2017 Jun 15Liu Mdoi: 10.1016/j.taap.2017.04.003
27211906Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitro.Int J Oncol2016 JulRogers-Broadway KRdoi: 10.3892/ijo.2016.3531
27996156α-enolase promotes tumorigenesis and metastasis via regulating AMPK/mTOR pathway in colorectal cancer.Mol Carcinog2017 MayZhan Pdoi: 10.1002/mc.22603
27301639PI3K/Akt/mTOR activation by suppression of ELK3 mediates chemosensitivity of MDA-MB-231 cells to doxorubicin by inhibiting autophagy.Biochem Biophys Res Commun2016 Aug 19Park JHdoi: 10.1016/j.bbrc.2016.06.057
28639903Targeting the mTOR pathway in breast cancer.Tumour Biol2017 JunLiu Jdoi: 10.1177/1010428317710825.
28005970Phosphorylated Mammalian Target of Rapamycin p-mTOR Is a Favorable Prognostic Factor than mTOR in Gastric Cancer.PLoS One2016 Dec 22Cao GDdoi: 10.1371/journal.pone.0168085
27746162Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.Cancer Lett2017 Jan 1Mimoto Rdoi: 10.1016/j.canlet.2016.10.015
27385486Mutant p53 and mTOR/PKM2 regulation in cancer cells.IUBMB Life2016 SepDando Idoi: 10.1002/iub.1534
26876207Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.Oncogene2016 Sep 1Zhou Jdoi: 10.1038/onc.2016.4
28574664Chemokine (CC motif) ligand 18 upregulates Slug expression to promote stem-cell like features by activating the mammalian target of rapamycin pathway in oral squamous cell carcinoma.Cancer Sci2017 AugWang Hdoi: 10.1111/cas.13289
28870807A natural product toosendanin inhibits epithelial-mesenchymal transition and tumor growth in pancreatic cancer via deactivating Akt/mTOR signaling.Biochem Biophys Res Commun2017 Nov 4Pei Zdoi: 10.1016/j.bbrc.2017.08.170
28716898TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer.Cancer Res2017 Sep 15Cooper JMdoi: 10.1158/0008-5472.CAN-17-0829
28923857MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway.Cancer Res2017 Nov 1Yu Tdoi: 10.1158/0008-5472.CAN-17-0671
27036037Age related increase in mTOR activity contributes to the pathological changes in ovarian surface epithelium.Oncotarget2016 Apr 12Bajwa Pdoi: 10.18632/oncotarget.8468.
26895472mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials.Oncotarget2016 May 10Rotundo MSdoi: 10.18632/oncotarget.7446.
29103666Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.Eur J Cancer2017 DecLe Rhun Edoi: 10.1016/j.ejca.2017.10.006
27009856mTOR regulates proteasomal degradation and Dp1/E2F1- mediated transcription of KPNA2 in lung cancer cells.Oncotarget2016 May 3Wang CIdoi: 10.18632/oncotarget.8170.
27150059Nesfatin-1/Nucleobindin-2 enhances cell migration, invasion, and epithelial-mesenchymal transition via LKB1/AMPK/TORC1/ZEB1 pathways in colon cancer.Oncotarget2016 May 24Kan JYdoi: 10.18632/oncotarget.9140.
27096957mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma.Oncotarget2016 May 31Stelloo Sdoi: 10.18632/oncotarget.8767.
27853903Does any drug to treat cancer target mTOR and iron hemostasis in neurodegenerative disorders?Biometals2017 FebJodeiri Farshbaf Mdoi: 10.1007/s10534-016-9981-x
27015560mTOR complex-2 stimulates acetyl-CoA and de novo lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer.Oncotarget2016 May 3Chen Ydoi: 10.18632/oncotarget.8279.
28741507mTOR Signaling Confers Resistance to Targeted Cancer Drugs.Trends Cancer2016 NovGuri Ydoi: 10.1016/j.trecan.2016.10.006
29185784miR-21 Inhibitors Modulate Biological Functions of Gastric Cancer Cells via PTEN/PI3K/mTOR Pathway.DNA Cell Biol2018 JanWang Pdoi: 10.1089/dna.2017.3922
27462867Genetic polymorphisms of mTOR and cancer risk: a systematic review and updated meta-analysis.Oncotarget2016 Aug 30Zining Jdoi: 10.18632/oncotarget.10805.
27517315Growth factor progranulin promotes tumorigenesis of cervical cancer via PI3K/Akt/mTOR signaling pathway.Oncotarget2016 Sep 6Feng Tdoi: 10.18632/oncotarget.11126.
27974704MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling.Oncotarget2017 Jan 31Offermann Adoi: 10.18632/oncotarget.13860.
27472392Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation.Oncotarget2016 Sep 6Henry REdoi: 10.18632/oncotarget.10859.
27863387Aberrant overexpression of ADAR1 promotes gastric cancer progression by activating mTOR/p70S6K signaling.Oncotarget2016 Dec 27Dou Ndoi: 10.18632/oncotarget.13354.
28427795Reappraisal to the study of 4E-BP1 as an mTOR substrate - A normative critique.Eur J Cell Biol2017 JunBatool Adoi: 10.1016/j.ejcb.2017.03.013
28569781Mitochondrial AKAP1 supports mTOR pathway and tumor growth.Cell Death Dis2017 Jun 1Rinaldi Ldoi: 10.1038/cddis.2017.241.
28661070microRNA-145-3p inhibits non-small cell lung cancer cell migration and invasion by targeting PDK1 via the mTOR signaling pathway.J Cell Biochem2018 JanChen GMdoi: 10.1002/jcb.26252
28899863A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles.Cancer Discov2017 NovRebecca VWdoi: 10.1158/2159-8290.CD-17-0741
29081412MiR-101 reduces cell proliferation and invasion and enhances apoptosis in endometrial cancer via regulating PI3K/Akt/mTOR.Cancer Biomark2017 Dec 12Zhang Sdoi: 10.3233/CBM-170620.
29393469TRIM28 promotes cervical cancer growth through the mTOR signaling pathway.Oncol Rep2018 AprLi Fdoi: 10.3892/or.2018.6235
29484437miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway.Oncol Rep2018 AprLiu Jdoi: 10.3892/or.2018.6268
28724614Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer.Genes Dev2017 Jun 15Audet-Walsh ??doi: 10.1101/gad.299958.117
29328491MicroRNA-let-7a regulates cell autophagy by targeting Rictor in gastric cancer cell lines MGC-803 and SGC-7901.Oncol Rep2018 MarFan Hdoi: 10.3892/or.2018.6194
29488612Piperine depresses the migration progression via downregulating the Akt/mTOR/MMP9 signaling pathway in DU145 cells.Mol Med Rep2018 MayZeng Ydoi: 10.3892/mmr.2018.8653
29807226MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway.Biomed Pharmacother2018 AugDai Cdoi: 10.1016/j.biopha.2018.05.077
29086897Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.Breast Cancer2018 JulAraki Kdoi: 10.1007/s12282-017-0812-x
29568966PPP2R2D, a regulatory subunit of protein phosphatase2A, promotes gastric cancer growth and metastasis via mechanistic target of rapamycin activation.Int J Oncol2018 JunYu Sdoi: 10.3892/ijo.2018.4329
29566977CO suppresses prostate cancer cell growth by directly targeting LKB1/AMPK/mTOR pathway in vitro and in vivo.Urol Oncol2018 JunYan Ydoi: 10.1016/j.urolonc.2018.02.013
28332630PML nuclear bodies contribute to the basal expression of the mTOR inhibitor DDIT4.Sci Rep2017 Mar 23Salsman Jdoi: 10.1038/srep45038.
29862445Expression of miRNAs Targeting mTOR and S6K1 Genes of mTOR Signaling Pathway Including miR-96, miR-557, and miR-3182 in Triple-Negative Breast Cancer.Appl Biochem Biotechnol2018 DecRazaviyan Jdoi: 10.1007/s12010-018-2773-8
30272366Clinical associations between ASCT2 and pmTOR in the pathogenesis and prognosis of epithelial ovarian cancer.Oncol Rep2018 DecGuo Hdoi: 10.3892/or.2018.6729
28484242Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells.Sci Rep2017 May 8Zhou Xdoi: 10.1038/s41598-017-01729-w.
30226616C16ceramide and sphingosine1phosphate/S1PR2 have opposite effects on cell growth through mTOR signaling pathway regulation.Oncol Rep2018 NovKim MHdoi: 10.3892/or.2018.6689
29449346Shikonin suppresses proliferation and induces apoptosis in endometrioid endometrial cancer cells via modulating miR-106b/PTEN/AKT/mTOR signaling pathway.Biosci Rep2018 Apr 13Huang Cdoi: 10.1042/BSR20171546
29133593Adipose-Derived VEGF-mTOR Signaling Promotes Endometrial Hyperplasia and Cancer: Implications for Obese Women.Mol Cancer Res2018 FebSahoo SSdoi: 10.1158/1541-7786.MCR-17-0466
30419950LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer.J Exp Clin Cancer Res2018 Nov 12Feng Mdoi: 10.1186/s13046-018-0947-4.
29384225Jolkinolide B inhibits glycolysis by downregulating hexokinase 2 expression through inactivating the Akt/mTOR pathway in non-small cell lung cancer cells.J Cell Biochem2018 JunGao Xdoi: 10.1002/jcb.26742
29978580Functional variant of MTOR rs2536 and survival of Chinese gastric cancer patients.Int J Cancer2019 Jan 15Cheng Ldoi: 10.1002/ijc.31656
30755508Repression of Human Papillomavirus Oncogene Expression under Hypoxia Is Mediated by PI3K/mTORC2/AKT Signaling.MBio2019 Feb 12Bossler Fdoi: 10.1128/mBio.02323-18.
29408410The role of mTOR-mediated signaling in the regulation of cellular migration.Immunol Lett2018 AprHolroyd AKdoi: 10.1016/j.imlet.2018.01.015

Differential Expression

Expression in 33 cancers

Mutations
CancerChrPosition Mutation TypedbSNPProtein-change Allele FreqRBD
BLCAchr111199661SilentNAL1329L0.17
BLCAchr111209408SilentnovelR1235R0.23
BLCAchr111130544Missense_MutationnovelQ1866H0.2
BLCAchr111122068Missense_MutationnovelP2241S0.22
BLCAchr111130609Missense_Mutationrs762176419E1845K0.44
BLCAchr111134452SilentnovelQ1715Q0.39
BLCAchr111124535Missense_MutationNAL2209V0.16
BLCAchr111237901Missense_Mutationrs566273004R717Q0.29
BLCAchr111228833SilentNAL955L0.21
BLCAchr111146701Missense_MutationnovelQ1554L0.1
BLCAchr111259320Missense_MutationnovelK30N0.32
BLCAchr111248089SilentnovelL282L0.13
BLCAchr111210832SilentNAL1212L0.34
BLCAchr111129800SilentnovelA1884A0.39
BLCAchr111108178Splice_Regionnovel0.41
BLCAchr111228731Missense_MutationnovelF989L0.36
BRCAchr111128041Missense_MutationnovelC1999F0.4
BRCAchr111157256SilentNAE1455E0.32
BRCAchr111144685Missense_MutationNAR1612P0.23
BRCAchr111127059Missense_MutationNAW2101L0.38
BRCAchr111259385Missense_Mutationrs769877976A9T0.68
BRCAchr111150146Missense_MutationNAA1517V0.29
BRCAchr111241670Missense_MutationnovelA475G0.34
BRCAchr111240526SilentNAL521L0.47
BRCAchr111122122Nonsense_MutationnovelQ2223*0.37
BRCAchr111114403SilentnovelE2405E0.06
BRCAchr111114815Missense_MutationNAE2388Q0.14
BRCAchr111109320Missense_MutationNAI2500F0.78
BRCAchr111210824Missense_MutationNAR1215T0.22
BRCAchr111146713Missense_MutationnovelL1550Q0.09
BRCAchr111128120Missense_MutationNAI1973F0.61
BRCAchr111117042SilentNAV2326V0.27
BRCAchr111228860SilentNAF946F0.22
BRCAchr111133168Missense_MutationnovelL1759R0.44
BRCAchr111213542Missense_MutationNAI1048L0.27
BRCAchr111234260Missense_MutationNAL738F0.28
BRCAchr111114872Missense_MutationnovelE2369Q0.51
BRCAchr111108184Missense_MutationnovelG2544A0.07
BRCAchr111129773SilentnovelS1893S0.13
BRCAchr111209391Missense_MutationnovelQ1241R0.05
BRCAchr111247689SilentNAL387L0.4
BRCAchr111114874Missense_MutationNAR2368Q0.22
BRCAchr111257040Missense_MutationNAL133V0.56
BRCAchr111127798SilentNAE2014E0.24
BRCAchr111210856SilentnovelI1204I0.08
CESCchr111128121SilentNAL1972L0.23
CESCchr1111066443'UTRnovel0.17
CESCchr1111074533'UTRnovel0.23
CESCchr111157220Missense_MutationNAM1467I0.24
CESCchr111124516Missense_MutationNAS2215Y0.39
CESCchr111213490Frame_Shift_DelnovelG1065Vfs*100.21
CESCchr111130747Missense_MutationNAE1799K0.43
CESCchr111108239Missense_MutationNAE2526K0.16
CESCchr111121339SilentNAL2280L0.31
CESCchr111114363Missense_Mutationrs587777900E2419K0.47
CESCchr111121339SilentNAL2280L0.27
CESCchr111231307Missense_MutationnovelR881H0.13
CESCchr111124589Missense_MutationNAD2191H0.28
CESCchr111209387SilentnovelG1242G0.26
CESCchr111124516Missense_Mutationrs587777894S2215F0.35
CESCchr111124604Missense_MutationnovelL2186V0.32
CESCchr111243187Missense_MutationNAE447Q0.39
COADchr111130747Missense_MutationNAE1799K0.41
COADchr111124516Missense_Mutationrs587777894S2215F0.65
COADchr111233409Nonsense_MutationNAE804*0.36
COADchr111238462Missense_Mutationrs748207893A648T0.12
COADchr111213450Missense_Mutationrs757645678M1078I0.28
COADchr111114399SilentnovelL2407L0.14
COADchr111213497Missense_MutationnovelL1063F0.3
COADchr111130675Missense_MutationnovelA1823T0.3
COADchr111126643Missense_MutationnovelP2169S0.43
COADchr111130661Silentrs769197073N1827N0.36
COADchr111117004Missense_MutationnovelR2339I0.08
COADchr111240523Silentrs369221365Y522Y0.49
COADchr111240377Missense_Mutationrs749766561T571M0.27
COADchr111117021Missense_MutationNAI2333M0.36
COADchr111139308Missense_Mutationrs587777895R1709H0.4
COADchr111259252Missense_MutationNAR53Q0.2
COADchr111144673Missense_MutationNAR1616H0.27
COADchr111259350SilentnovelS20S0.2
COADchr111216158Missense_MutationNAT1036N0.12
COADchr111124516Missense_Mutationrs587777894S2215F0.22
COADchr111231353Missense_MutationnovelE866K0.18
COADchr111129784Missense_MutationNAR1890C0.4
COADchr111209382Missense_MutationNAA1244E0.28
COADchr111253930Missense_MutationNAA250V0.39
COADchr111128037SilentnovelE2000E0.1
COADchr111243121Missense_Mutationrs763879621A469T0.3
COADchr111233453Missense_MutationnovelD789V0.24
COADchr111243143Silentrs753907829A461A0.24
COADchr111259349Missense_Mutationrs149221273V21I0.25
COADchr111122122Missense_MutationNAQ2223K0.57
COADchr111237963Missense_MutationNAL696F0.18
COADchr111128926Missense_MutationNAG1914C0.47
COADchr111145002Missense_MutationNAA1577V0.44
COADchr111213446Missense_Mutationrs751901845R1080C0.44
COADchr111232487Frame_Shift_DelNAF821Lfs*340.28
COADchr111257151Missense_MutationnovelV96M0.31
COADchr111248003Missense_Mutationrs150146024R311H0.17
COADchr111259343Nonsense_MutationnovelQ23*0.3
COADchr111157182Missense_Mutationrs780930764R1480H0.28
COADchr111130767Missense_MutationNAA1792V0.35
COADchr111112896Missense_MutationNAR2441Q0.69
COADchr1111074423'UTRnovel0.12
COADchr111238594Missense_MutationNAR604C0.39
COADchr111256029Missense_MutationnovelR223H0.07
COADchr1111074673'UTRrs7687358470.22
COADchr111228722Missense_MutationnovelQ992H0.33
COADchr111258503Missense_MutationnovelG85S0.27
COADchr111204597Missense_MutationnovelC1303F0.62
COADchr111130747Missense_MutationNAE1799K0.55
COADchr111167480Missense_MutationNAG1431R0.38
COADchr111126713SilentnovelD2145D0.08
COADchr111127775Missense_MutationnovelL2022P0.24
COADchr111167494Missense_Mutationrs35509012P1426L0.18
DLBCchr111139632Nonsense_MutationnovelW1633*0.09
ESCAchr111127746Missense_MutationnovelE2032K0.46
ESCAchr111232486Missense_MutationnovelI822V0.25
ESCAchr111117008Missense_MutationnovelD2338N0.37
ESCAchr111228901Missense_MutationnovelE933K0.27
ESCAchr111144648Missense_MutationnovelQ1624H0.46
GBMchr111209330Missense_MutationnovelS1261R0.04
GBMchr111199628Missense_MutationnovelS1340R0.07
GBMchr1111074083'UTRnovel0.16
GBMchr111199267Missense_MutationnovelS1415F0.47
GBMchr111124517Missense_MutationnovelS2215T0.87
GBMchr111144995Frame_Shift_DelnovelA1579Gfs*690.43
GBMchr111114338Missense_MutationNAL2427Q0.3
GBMchr111130571Missense_MutationnovelE1857D0.16
GBMchr111130875Intronnovel0.16
GBMchr111256144Nonsense_MutationNAQ185*0.25
GBMchr111130815Intronnovel0.09
GBMchr111130587Missense_MutationnovelE1852V0.14
GBMchr1111074003'UTRnovel0.69
GBMchr111134372Missense_MutationnovelE1742G0.05
GBMchr111130747Missense_MutationNAE1799K0.27
HNSCchr111228799Missense_MutationnovelH967Y0.35
HNSCchr111129759Missense_MutationnovelN1898S0.13
HNSCchr111146791Missense_MutationnovelG1524V0.29
HNSCchr111259283Nonsense_MutationnovelE43*0.17
HNSCchr1111073423'UTRnovel0.11
HNSCchr111238600Missense_MutationnovelF602L0.53
HNSCchr111126634Missense_MutationnovelL2172M0.41
HNSCchr111127094Missense_Mutationrs542723817M2089I0.17
HNSCchr111139643Missense_MutationnovelV1630I0.2
HNSCchr111237925Missense_MutationnovelE709G0.26
KICHchr111127790Missense_MutationnovelI2017T0.33
KICHchr111114338Missense_MutationNAL2427R0.3
KIRCchr111128107Missense_Mutationrs587777893T1977K0.36
KIRCchr111122106Missense_MutationNAI2228T0.46
KIRCchr111157246Missense_MutationNAA1459P0.23
KIRCchr111128107Missense_MutationNAT1977R0.24
KIRCchr111114324In_Frame_DelnovelR2430_L2431del0.1
KIRCchr111157173Missense_Mutationrs786205165C1483F0.04
KIRCchr111157242Missense_MutationNAL1460P0.31
KIRCchr111247835Missense_MutationnovelE367V0.32
KIRCchr111157265Missense_MutationNAK1452N0.3
KIRCchr111234211Missense_MutationnovelR755C0.26
KIRCchr111157173Missense_MutationNAC1483Y0.21
KIRCchr111128107Missense_MutationNAT1977R0.23
KIRCchr111114354Missense_MutationNAV2422I0.4
KIRCchr111109318Missense_MutationNAI2500M0.22
KIRCchr111167473Missense_MutationNAL1433S0.28
KIRCchr111117020Missense_MutationNAL2334V0.13
KIRCchr111114402Missense_MutationNAV2406M0.31
KIRCchr111157233Missense_MutationNAY1463S0.18
KIRCchr111129788Missense_MutationNAF1888L0.5
KIRCchr111130637Silentrs765484322A1835A0.08
KIRCchr111231369Missense_MutationNAK860N0.04
KIRCchr111128120Missense_MutationNAI1973F0.11
KIRCchr111150141Missense_MutationNAA1519T0.21
KIRCchr111124516Missense_MutationNAS2215Y0.6
KIRCchr111108237SilentNAE2526E0.25
KIRPchr111247733Missense_MutationNAV373L0.22
KIRPchr111210832SilentNAL1212L0.11
KIRPchr111213546SilentNAT1046T0.39
KIRPchr111114338Missense_MutationNAL2427Q0.32
KIRPchr111124516Missense_MutationNAS2215Y0.32
LAMLchr111133170Missense_MutationnovelQ1758H0.19
LAMLchr111233413SilentnovelI802I0.05
LAMLchr111243231Missense_Mutationrs199646229A432V0.18
LAMLchr111130609Missense_Mutationrs762176419E1845K0.14
LGGchr111117039Missense_MutationNAM2327I0.75
LGGchr111124584SilentNAL2192L0.21
LGGchr111122101Missense_MutationNAL2230V0.79
LGGchr111122082Missense_MutationnovelL2236H0.53
LGGchr111145029Missense_MutationnovelR1568M0.32
LGGchr111121269Missense_MutationnovelW2304R0.31
LGGchr111124513Missense_MutationNAL2216P0.83
LIHCchr111109317Missense_MutationNAI2501F0.08
LIHCchr111144737Missense_MutationNAM1595V0.68
LIHCchr111238043Missense_MutationNAD670H0.32
LIHCchr111256931Splice_SiteNAX168_splice0.67
LIHCchr111241592Missense_MutationnovelI501N0.32
LIHCchr111124516Missense_MutationNAS2215Y0.13
LUADchr111124617Silentrs17229235E2181E0.24
LUADchr111232437Missense_MutationNAQ838L0.17
LUADchr111167493SilentNAP1426P0.05
LUADchr111248023Missense_MutationNAM304I0.11
LUADchr1111074573'UTRnovel0.09
LUADchr111167488Missense_MutationNAA1428V0.39
LUADchr111139611SilentnovelR1640R0.08
LUADchr111259353SilentnovelV19V0.21
LUADchr111210831Missense_MutationNAI1213V0.2
LUADchr1111074733'UTRnovel0.21
LUADchr111240376SilentNAT571T0.35
LUADchr111243156Missense_MutationnovelD457G0.27
LUADchr111124543Missense_MutationNAN2206S0.12
LUADchr111231376Missense_MutationNAY858C0.13
LUADchr111121264SilentnovelL2305L0.12
LUADchr111157156Nonsense_MutationnovelE1489*0.25
LUADchr111240413Missense_MutationnovelK559M0.07
LUADchr111257159Frame_Shift_InsnovelL93Pfs*270.39
LUADchr111238576Missense_MutationnovelF610L0.11
LUADchr111157226Missense_MutationNAK1465N0.06
LUADchr111134415Missense_MutationNAA1728S0.57
LUADchr111238402Missense_MutationNAD668Y0.33
LUADchr111240482Missense_MutationNAQ536P0.32
LUADchr111122037Missense_MutationNAR2251Q0.16
LUADchr111237935Missense_MutationNAE706Q0.11
LUADchr111259388Missense_MutationNAA8S0.64
LUADchr111204665Missense_MutationNAW1280C0.3
LUADchr111237906SilentNAV715V0.4
LUADchr111258539Missense_MutationnovelE73Q0.05
LUADchr111204629SilentnovelL1292L0.11
LUADchr111213552Missense_Mutationrs532979867M1044I0.21
LUADchr111228671SilentnovelR1009R0.16
LUADchr111212421Missense_Mutationrs151082401Y1151C0.17
LUADchr111121334Missense_MutationnovelQ2282R0.22
LUADchr111210815Missense_MutationnovelK1218M0.27
LUADchr111253917SilentnovelG254G0.51
LUADchr111115436Missense_MutationnovelS2350I0.05
LUADchr111121293Missense_MutationnovelG2296W0.18
LUADchr111228828Missense_MutationNAR957Q0.36
LUADchr111256105Missense_MutationnovelV198L0.39
LUADchr111121992Missense_MutationNAR2266P0.23
LUSCchr111133157Missense_MutationNAG1763C0.21
LUSCchr111133158Missense_MutationNAQ1762H0.22
LUSCchr111124532Missense_MutationNAA2210P0.46
LUSCchr111114401Missense_MutationNAV2406A0.31
LUSCchr111199340Nonsense_MutationnovelR1391*0.11
LUSCchr111117055Missense_MutationnovelR2322H0.08
LUSCchr111131321Intronnovel0.63
LUSCchr111109683SilentnovelT2471T0.22
LUSCchr111253916Missense_MutationnovelM255V0.6
LUSCchr111126674Silentrs201488400P2158P0.16
LUSCchr111157275Missense_MutationnovelW1449S0.08
LUSCchr111247643Nonsense_MutationNAR403*0.23
LUSCchr111237879SilentNAA724A0.38
LUSCchr111237939SilentnovelV704V0.22
LUSCchr111114884Missense_MutationnovelA2365S0.26
LUSCchr111237956Missense_MutationNAA699P0.6
LUSCchr111258552Missense_MutationNAN68K0.27
LUSCchr111237847Missense_MutationNAI735S0.19
LUSCchr111238584Missense_MutationNAA607V0.35
LUSCchr111128926Missense_MutationnovelG1914R0.18
LUSCchr111121365Missense_MutationNAA2272S0.21
LUSCchr111228801Missense_MutationnovelH966R0.2
LUSCchr111127752Missense_MutationnovelG2030S0.13
OVchr111139545SilentnovelK1662K0.15
OVchr111234213Missense_MutationNAA754G0.32
OVchr111259267In_Frame_InsnovelV48delinsANERKGGILAI0.1
OVchr111128041Missense_MutationnovelC1999F0.08
OVchr111139545SilentnovelK1662K0.07
OVchr111127656Missense_MutationnovelP2062S0.11
OVchr111248093Missense_Mutationrs757384321R281H0.15
OVchr111139425Missense_MutationnovelH1670R0.04
OVchr111240431Missense_MutationNAR553H0.07
OVchr111114454Splice_SitenovelX2389_splice0.29
OVchr111157240Missense_MutationNAV1461L0.86
OVchr111247826Missense_MutationNAF370Y0.23
OVchr111122031Missense_MutationnovelY2253F0.12
OVchr111231326Missense_MutationNAE875K0.18
OVchr111234175Missense_MutationnovelL767V0.03
OVchr111127794Frame_Shift_InsnovelL2016Tfs*100.16
OVchr111243230SilentnovelA432A0.1
OVchr111209314Missense_MutationnovelK1267Q0.04
OVchr111128104Missense_MutationnovelV1978E0.02
OVchr111157198Missense_MutationnovelE1475Q0.09
OVchr111157199SilentnovelP1474P0.08
OVchr111259289Missense_Mutationrs758668050A41S0.61
OVchr111146727Missense_MutationnovelF1545L0.05
OVchr111258525Missense_MutationnovelS77R0.19
OVchr111248007Missense_MutationnovelP310S0.07
OVchr111212881Missense_Mutationrs529153687A1105T0.79
PAADchr111133086Missense_MutationnovelW1786C0.08
PAADchr1111074263'UTRnovel0.16
PAADchr111134464Splice_Regionrs769706061I1711I0.11
PAADchr111210873Missense_MutationnovelL1199M0.17
PAADchr111257005Silentrs757191894Y144Y0.16
PAADchr111231047Missense_Mutationrs376873727R886H0.27
PCPGchr111109320Missense_MutationNAI2500F0.23
PRADchr111150192Missense_Mutationrs748220176T1502A0.19
PRADchr111256075Nonsense_MutationnovelG208*0.07
PRADchr111130550Silentrs762660728P1864P0.08
PRADchr111128107Missense_MutationNAT1977R0.06
PRADchr111129773SilentnovelS1893S0.26
PRADchr111130633Missense_MutationnovelT1837A0.35
PRADchr111199636Missense_MutationnovelI1338L0.48
PRADchr111209410Missense_MutationnovelR1235W0.43
READchr111130646SilentnovelA1832A0.14
READchr111109305Nonsense_MutationNAR2505*0.1
READchr111128947Missense_MutationNAL1907F0.48
SKCMchr111240381Missense_MutationNAL570F0.54
SKCMchr111130747Missense_MutationNAE1799K0.48
SKCMchr111240437Missense_MutationNAP551L0.48
SKCMchr111128943Missense_MutationnovelT1908I0.25
SKCMchr111127683Missense_MutationnovelP2053A0.36
SKCMchr111109320Missense_MutationNAI2500F0.06
SKCMchr111259392SilentNAP6P0.14
SKCMchr111212881Missense_Mutationrs529153687A1105T0.21
SKCMchr111238037Missense_MutationNAR672C0.24
SKCMchr111230944SilentNAS920S0.38
SKCMchr111144678SilentnovelI1614I0.27
SKCMchr111117042SilentNAV2326V0.28
SKCMchr111126694Missense_Mutationrs752458445R2152C0.32
SKCMchr111129784Missense_MutationNAR1890C0.14
SKCMchr111139608SilentNAS1641S0.28
SKCMchr111144674Missense_Mutationrs17848545R1616C0.25
SKCMchr111139355SilentNAH1693H0.73
SKCMchr111134374SilentnovelQ1741Q0.31
SKCMchr111167492Missense_MutationnovelE1427K0.57
SKCMchr111247873SilentnovelS354S0.27
SKCMchr111257130Missense_MutationnovelR103G0.25
SKCMchr111114371Missense_MutationNAA2416V0.52
SKCMchr111121364Missense_MutationNAA2272V0.32
SKCMchr111240343SilentnovelI582I0.42
SKCMchr111126686Silentrs201706131Q2154Q0.46
SKCMchr111238480Missense_MutationNAH642Y0.18
SKCMchr111233434SilentNAI795I0.05
SKCMchr111240541SilentNAA516A0.3
SKCMchr111240450Missense_MutationNAL547F0.51
SKCMchr111114348Missense_MutationnovelD2424N0.09
SKCMchr111238511In_Frame_InsnovelT631_P632insA0.03
SKCMchr111243224SilentNAF434F0.26
SKCMchr111109371Splice_SiteNAX2483_splice0.43
SKCMchr111114359Missense_MutationNAA2420V0.39
SKCMchr111127130Missense_MutationNAD2077E0.3
SKCMchr111228756Missense_MutationnovelS981F0.48
SKCMchr111256024Missense_MutationnovelP225S0.4
SKCMchr111240437Missense_MutationNAP551L0.42
SKCMchr111247695SilentnovelN385N0.17
SKCMchr111247696Missense_MutationnovelN385I0.17
SKCMchr111139369SilentNAL1689L0.58
SKCMchr111128018Nonsense_MutationNAQ2007*0.29
SKCMchr111139609Missense_Mutationrs772556623S1641F0.28
SKCMchr111126684Missense_MutationNAS2155F0.16
SKCMchr111130667SilentNAI1825I0.18
SKCMchr111228916Missense_MutationNAD928N0.32
SKCMchr111124540Missense_MutationNAT2207I0.28
SKCMchr111130573Missense_Mutationrs779045714E1857K0.88
SKCMchr111139644Silentrs186504696I1629I0.24
SKCMchr111139608SilentNAS1641S0.41
SKCMchr111139609Missense_Mutationrs772556623S1641F0.41
SKCMchr111204701Splice_RegionNAA1268A0.23
SKCMchr111213459SilentNAI1075I0.54
SKCMchr111126768Missense_MutationNAS2127F0.67
SKCMchr111129751Nonsense_MutationnovelQ1901*0.12
SKCMchr111256986SilentNAR151R0.27
STADchr111212346Missense_Mutationrs557533784T1176M0.26
STADchr111240523Silentrs369221365Y522Y0.23
STADchr111243280Missense_MutationNAT416A0.44
STADchr111144649Missense_MutationnovelQ1624R0.1
STADchr111230961Missense_MutationnovelV915F0.25
STADchr111115469Splice_SiteNAX2339_splice0.25
STADchr111213489Frame_Shift_InsnovelE1066*0.21
STADchr111124583Missense_MutationNAR2193C0.15
STADchr111144650Nonsense_MutationNAQ1624*0.18
STADchr111243148Nonsense_MutationNAR460*0.32
STADchr111247699Missense_MutationNAK384R0.34
STADchr111209451Missense_MutationnovelT1221I0.38
STADchr111241663Missense_MutationNAQ477H0.36
STADchr111230975Missense_MutationNAR910Q0.21
STADchr111108220Missense_MutationNAA2532V0.28
STADchr111109318Missense_MutationNAI2500M0.31
STADchr111238594Missense_MutationNAR604C0.34
STADchr111253900Missense_MutationnovelR260Q0.13
STADchr111253880Missense_MutationNAI267V0.09
STADchr111210861Nonsense_MutationNAR1203*0.29
STADchr111213531Silentrs147272284T1051T0.21
STADchr111121360SilentNAP2273P0.08
STADchr111240377Missense_Mutationrs749766561T571M0.36
STADchr111238576Missense_MutationNAF610V0.11
STADchr111243114Missense_MutationNAK471T0.28
STADchr111121288Silentrs763361130D2297D0.14
STADchr111121299Missense_MutationNAT2294A0.13
STADchr1111074603'UTRrs3762433070.42
STADchr111144673Missense_MutationNAR1616H0.22
STADchr111253871Missense_MutationNAE270K0.21
STADchr111122115Missense_MutationnovelY2225C0.25
STADchr111144750Missense_MutationNAM1590I0.06
STADchr111231308Missense_MutationNAR881C0.33
STADchr111237887Missense_MutationNAN722D0.4
STADchr111234178Frame_Shift_DelnovelR766Dfs*110.11
STADchr111231417SilentNAL844L0.07
STADchr111243166Missense_MutationnovelR454C0.3
STADchr111228731SilentNAF989F0.15
STADchr111157177Missense_MutationNAR1482C0.31
STADchr111213531Silentrs147272284T1051T0.31
STADchr111228828Missense_MutationNAR957Q0.35
STADchr111124509SilentNAR2217R0.19
STADchr111248004Missense_Mutationrs200901835R311C0.19
STADchr111248094Missense_MutationNAR281C0.18
THCAchr111258567Frame_Shift_InsnovelF63Lfs*70.05
THYMchr111109684Missense_MutationNAT2471M0.32
UCECchr111108247Missense_MutationNAT2523M0.57
UCECchr111128467Missense_MutationNAR1966Q0.22
UCECchr111109318Missense_MutationNAI2500M0.37
UCECchr111253871Missense_MutationNAE270K0.32
UCECchr111257065Missense_MutationNAE124D0.31
UCECchr111146754SilentNAI1536I0.33
UCECchr111248073Nonsense_MutationnovelE288*0.07
UCECchr111126694Missense_Mutationrs752458445R2152C0.14
UCECchr111130675Missense_MutationnovelA1823T0.08
UCECchr111234168Missense_Mutationrs753826002R769H0.28
UCECchr111128096Missense_MutationNAK1981E0.25
UCECchr111124516Missense_MutationNAS2215Y0.26
UCECchr111144745Missense_MutationNAS1592Y0.47
UCECchr111247698Missense_MutationNAK384N0.31
UCECchr1111066813'UTRnovel0.53
UCECchr111139643Missense_MutationnovelV1630I0.38
UCECchr111247725SilentnovelQ375Q0.46
UCECchr111259326SilentnovelG28G0.29
UCECchr111130747Missense_MutationNAE1799K0.46
UCECchr111256117Missense_MutationNAI194V0.46
UCECchr1111069003'UTRnovel0.38
UCECchr111109305Nonsense_MutationNAR2505*0.4
UCECchr111124516Missense_MutationNAS2215Y0.4
UCECchr111130641Missense_Mutationrs142403193T1834M0.5
UCECchr111114875Nonsense_MutationnovelR2368*0.13
UCECchr111124516Missense_MutationNAS2215Y0.41
UCECchr111199302Missense_MutationnovelE1403D0.52